WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > ACOBIOM
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Webinar
Conference
Labiotech | February 03, 2020
RNA vaccine developer CureVac will receive a grant of up to €8.3M from a global partnership to develop an mRNA vaccine against the new coronavirus strain from China. The agreement follows on from an existing collaboration launched in 2019, when the Coalition for Epidemic Preparedness Innovations, or CEPI, granted CureVac €30M to develop facilities that can ‘print’ mRNA vaccines. The aim of the new grant is to help CureVac’s preclinical-stage mRNA vaccine for the coron...
FierceBiotech | February 10, 2020
Britain-based biotech Enterprise Therapeutics has hired Novartis Venture Fund managing director David Morris, M.D., as its next chief medical officer. Morris, who will continue to serve as the fund’s operating partner, will lead Enterprise’s development strategy and drive its two lead respiratory programs through the clinic. These are ETD002, a first-in-class TMEM16A potentiator, and ETD001, an ENaC blocker, both of which are hoping to help cystic fibrosis (CF) patients....
Sana Biotechnology | June 23, 2020
A startup company developing in vivo and ex vivo cell therapies has raised a significant chunk of funding for its initial financing from life science and technology venture capital as well as pension plans and others.Seattle-based Sana Biotechnology said Tuesday that it had raised more than $700 million from a wide range of investors, including ARCH Venture Partners, Flagship Pioneering, the Canada Pension Plan Investment Board, Baillie Gifford, F-Prime Capital, the Alaska Permanent Fund, ...
Medical
Andelyn Biosciences, Inc. | January 16, 2024
Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Armatus Bio to accelerate manufacturing of their gene therapy treatment for Charcot-Marie-Tooth Type 1A (CMT1A), a rare genetic neurological disease associated with independence-limiting disability and risk of fatal complications that has no approved therapies today. The partnership will seek to maximize program efficiency and spee...
Industrial Impact, Medical
Whitepaper
MedTech
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE